NCT01955720View on ClinicalTrials.gov

Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2014

Conditions
Hemorrhage
Interventions
DRUG

BI 655075

DRUG

BI 655075

DRUG

Placebo

DRUG

BI 655075

DRUG

Placebo

DRUG

Placebo

DRUG

Placebo

DRUG

BI 655075

Trial Locations (1)

Unknown

1321.2.1 Boehringer Ingelheim Investigational Site, Antwerp

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY